Subscribe to our Newsletters !!


Merck begins enrollment for COVID-19 vaccine preliminary

United States drugmaker Merck & Co Inc has begun recruiting participants into its early-stage COVID-19 vaccine study, according to the government database The phase 1/2 trial, which is based in Belgium, intends to recruit 260 healthy participants to check the experimental vaccine V591, which it gained access to as a member of its May

Scepter™ 3.0 Instrument for Wireless Cell Counting Precision launched by Merck

Merck announce the launch of its new Scepter™ 3.0 handheld automated cell counter, a solution that enables convenient, on-demand cell volume, cell diameter and cell concentration data. The device uses precision microfluidics to measure and count cells via electrical impedance within 30 seconds. The Scepter™ 3.0 cell counter offers researchers true automation without the risk

SignalChem Enters a Clinical Trial Collaboration with Merck to Evaluate the Effect of SLC-391 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

VANCOUVER, BRITISH COLUMBIA – March 25, 2021 – Life Science Newswire – SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, announces a collaboration with Merck, known as MSD outside of the United States and Canada, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with

Merck India inaugurates its R&D Excellence Centre in Bangalore

Bangalore, India: Merck, a leading science & technology company in the business of healthcare, life science & electronics, today announced the inauguration of its Healthcare R&D Excellence Centre facility in Bangalore. The Merck India R&D Excellence Centre contributes to the company’s Healthcare Research & Development (R&D) ambition of delivering the health care remedies of tomorrow,